4.6 Editorial Material

Natural Killer Cells in Sepsis: Detrimental Role for Final Outcome

期刊

CRITICAL CARE MEDICINE
卷 42, 期 6, 页码 1579-1580

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCM.0000000000000352

关键词

interferon-gamma; natural killer cells; neutrophils; outcome; severe sepsis

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Dermatology

Modulation of keratin deposition and pathogenesis of hidradenitis suppurativa: evidence coming from pachyonychia congenita

Evangelos J. Giamarellos-Bourboulis

BRITISH JOURNAL OF DERMATOLOGY (2022)

Editorial Material Dermatology

Keratinocytes as drivers of hidradenitis suppurativa inflammation: need for priming

Evangelos J. Giamarellos-Bourboulis

BRITISH JOURNAL OF DERMATOLOGY (2023)

Review Microbiology

Probiotics in Functional Dyspepsia

Georgios Tziatzios, Paraskevas Gkolfakis, Gabriela Leite, Ruchi Mathur, Georgia Damoraki, Evangelos J. J. Giamarellos-Bourboulis, Konstantinos Triantafyllou

Summary: Functional dyspepsia (FD) is a common disorder with no definitive, universal treatment. Probiotics have been suggested as a potential therapeutic option for FD due to their effects on gastrointestinal symptoms in patients with Irritable Bowel Syndrome (IBS). However, the evidence for the efficacy of probiotics in FD remains unclear. This review aims to summarize the available evidence for the use of probiotics in FD.

MICROORGANISMS (2023)

Article Hematology

An active new formulation of iron carried by aspartyl casein for iron-deficiency anemia: results of the ACCESS trial

Maria Tsilika, John Mitrou, Nikolaos Antonakos, Ioulia K. Tseti, Georgia Damoraki, Konstantinos Leventogiannis, Evangelos J. Giamarellos-Bourboulis

Summary: The clinical trial of the new oral iron formulation, Fe-ASP, demonstrates its non-inferiority to ferrous sulfate in increasing hemoglobin levels and improving global score and reducing iron-deficiency anemia-related physical signs.

ANNALS OF HEMATOLOGY (2023)

Article Infectious Diseases

REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI

Theodossis Papavramidis, Ivan Gentile, Anna Maria Cattelan, Laura Magnasco, Pierluigi Viale, Daniela Francisci, Diamantis P. Kofteridis, Giusy Tiseo, Evangelos J. Giamarellos-Bourboulis, Filippo Lagi, Simone Mornese Pinna, Federico D'Amico, Lucia La Ferla, Periklis Panagopoulos, Gianni Gattuso, Nikolaos V. Sipsas, Alessandro Ruggieri, Agnese Cattaneo, Luciana Corio, Alessandro Comandini, Patrizia Mascagni, Matteo Bassetti

Summary: A multicentre, observational, retrospective study showed that dalbavancin can significantly reduce hospital stay, decrease healthcare costs, and improve treatment efficacy and safety for patients with acute bacterial skin and skin-structure infections.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)

Article Biochemistry & Molecular Biology

Evaluation of the Novel Sepsis Biomarker Host-Derived Delta-like Canonical Notch Ligand 1-A Secondary Analysis of 405 Patients Suffering from Inflammatory or Infectious Diseases

Tobias Hoelle, Patrick Rehn, Konstantinos Leventogiannis, Antigone Kotsaki, Theodora Kanni, Nikolaos Antonakos, Christos Psarrakis, Georgia Damoraki, Judith Schenz, Felix C. F. Schmitt, Florian Uhle, Markus A. Weigand, Evangelos J. Giamarellos-Bourboulis, Maximilian Dietrich

Summary: This study evaluated the potential of Host-Derived Delta-like Canonical Notch Ligand 1 (DLL1) as a biomarker for diagnosing sepsis. Results showed that plasma levels of soluble DLL1 were significantly elevated in patients with sepsis compared to those with uncomplicated infections and sterile inflammation. DLL1 demonstrated better diagnostic performance for sepsis compared to other biomarkers such as C-reactive protein, procalcitonin, and White Blood Cell count.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Letter Dermatology

Immune Classification of Hidradenitis Suppurativa: Modulation by Secukinumab

Dimitra Stergianou, Styliani Micha, Vassiliki Tzanetakou, Theodora Kanni, Theologia Gkavogianni, Alexandros Katoulis, Evangelos J. Giamarellos-Bourboulis

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Article Multidisciplinary Sciences

Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study

Francesco Vladimiro Segala, Emanuele Rando, Federica J. Salvati, Marcantonio Negri, Francesca Catania, Flavia Sanmartin, Rita Murri, Evangelos Giamarellos-Bourboulis, Massimo Fantoni

Summary: A retrospective cohort study found that early administration of anakinra, an interleukin-1 receptor antagonist, guided by baseline suPAR levels, can prevent disease progression and death in COVID-19 patients. In the absence of suPAR testing, the SCOPE score can be used as an alternative for treatment decisions.

PLOS ONE (2023)

Article Health Care Sciences & Services

Modified SCOPE (mSCOPE) Score as a Tool to Predict Mortality in COVID-19 Critically Ill Patients

Stavroula Zanelli, Agamemnon Bakakos, Zoi Sotiropoulou, Andriana I. Papaioannou, Evangelia Koukaki, Efstathia Potamianou, Anna Kyriakoudi, Evangelos Kaniaris, Petros Bakakos, Evangelos J. Giamarellos-Bourboulis, Antonia Koutsoukou, Nikoletta Rovina

Summary: This study assessed the modified Severe COvid Prediction Estimate score (mSCOPE) as a predictor of mortality in ICU-admitted severe COVID-19 pneumonia patients. The results showed that patients with higher mSCOPE scores had a higher mortality rate and were correlated with disease severity, comorbidity severity, days on mechanical ventilation, and days of ICU stay. The mSCOPE score can be a useful tool for risk stratification in patients with severe COVID-19.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Editorial Material Dermatology

Interleukin-17A derived from mast cells: evidence for an autoinflammatory loop in hidradenitis suppurativa?

Evangelos J. Giamarellos-Bourboulis

BRITISH JOURNAL OF DERMATOLOGY (2023)

Article Pathology

Biomarkers to guide immunomodulatory treatment: where do we stand?

Evdoxia Kyriazopoulou, Evangelos J. Giamarellos-Bourboulis, Karolina Akinosoglou

Summary: This review summarizes the current progress in the development of biomarkers to guide immunotherapy in oncology, rheumatology, and critical illness.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2023)

Correction Critical Care Medicine

Sepsis, a call for inclusion in the work plan of the European Center for Disease Prevention and Control (vol 49, pg 1138, 2023)

Evangelos J. Giamarellos-Bourboulis, Annelies S. Zinkernagel, Edoardo De Robertis, Elie Azoulay, Daniele De Luca

INTENSIVE CARE MEDICINE (2023)

Letter Critical Care Medicine

Sepsis, a call for inclusion in the work plan of the European Center for Disease Prevention and Control

Evangelos J. Giamarellos-Bourboulis, Annelies S. Zinkernagel, Edoardo De Robertis, Elie Azoulay, Daniele De Luca

INTENSIVE CARE MEDICINE (2023)

Article Cardiac & Cardiovascular Systems

Analysis of inflammatory protein profiles in the circulation of COVID-19 patients identifies patients with severe disease phenotypes

Nick Keur, Maria Saridaki, Isis Ricano-Ponce, Mihai G. Netea, Evangelos J. Giamarellos-Bourboulis, Vinod Kumar

Summary: This study identified protein biomarkers associated with COVID-19 severity through the measurement of plasma protein levels. It also identified three clinical endotypes of the disease. These findings suggest that circulating proteins may be useful for predicting COVID-19 outcomes and may be applicable to other populations.

RESPIRATORY MEDICINE (2023)

Article Multidisciplinary Sciences

A randomized clinical trial of bermekimab treatment for clinical improvement of systemic sclerosis

Nicky Solomonidi, Panayiotis G. Vlachoyiannopoulos, Maria Pappa, Georgia Liantinioti, Sofia Ktena, Evangelos Theotikos, Antonia Elezoglou, Mihai G. Netea, Evangelos J. Giamarellos-Bourboulis

Summary: This study found that increased concentrations of IL-1 alpha are present in SSc patients. Treatment with the IL-1 alpha blocking antibody, bermekimab, effectively inhibits disease progression and reduces inflammation.

ISCIENCE (2023)

暂无数据